inhibitor

(redirected from saquinavir)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to saquinavir: ritonavir, nelfinavir, Saquinavir mesylate
See: deterrent
References in periodicals archive ?
The original Invirase formulation of saquinavir comprised hard-gel capsules (HGC) that were troubled by poor bioavailability and large pill burden.
These were followed by indinavir (PI) with ritonavir (PI), saquinavir (PI) with efavirenz, and saquinavir with ritonavir.
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
El Frenpa VIH organiza un planton frente al Centro Medico Nacional para exigir acceso a los medicamentos; como resultado, al mes siguiente el Diario Oficial de la Federacion publica la inclusion de los inhibidores de proteasa (indinavir, saquinavir y ritonavir) en el Catalogo de Medicamentos del IMSS.
Archibald Chimuka, director of Varichem Pharmaceutical in Zimbabwe, believes that "the advantages of this agreement go beyond the simple production of saquinavir in that they translate into an improvement in the whole of our health system at a technical level and in terms of quality.
announced today the launch of a new drug for HIV (Human Immunodeficiency Virus) infection, HIV Protease inhibitor 'INVIRASE(R) Tablet 500 mg' (generic name: saquinavir mesilate), on September 15.
The tuberculosis treatment rifabutin, for example, should not be used with the protease inhibitor saquinavir for this reason.
In 1992, the year Edwin died, tennis great Arthur Ashe announced he had AIDS; the Centers for Disease Control and Prevention estimated 140,000 168,000 persons were living with AIDS in the United States (2); the International AIDS Society moved its 8th International Conference from Boston to Amsterdam in protest of US policy on HIV-infected travelers; and the Food and Drug Administration was some 3 years off approving the first protease inhibitor, saquinavir.
The increased clearance of saquinavir may be due to induction of hepatic and/or intestinal CYP3A4.
43) Results from a third evaluation of potential interactions between sildenafil and protease inhibitors indicated that the PDE5 inhibitor did not alter the pharmacokinetics of ritonavir or saquinavir but that coadministration of either protease inhibitor dramatically increased plasma levels of sildenafil.
December 6, 1995: the FDA approves saquinavir (Invirase) in a record 97 days.
The Guidelines for the Use of Antiretroviral Agents in HIV-Y-Infected Adults and Adolescents has been revised to include up-to-date drug information, including updated information on nevirapine hepatotoxicity risks, the interaction between rifampin and ritonavirboosted saquinavir, new pregnancy data for efavirenz, and new contraindications and warnings for ritonavir and lopinavir/ritonavir use.